SCHEMBL17845330

SCHEMBL17845330

CNc1c([N+](=O)[O-])cccc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
TDP1 Q9NUW8 3/20 0.44
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GPR35 Q9HC97 1/20 0.40
CYP3A4 P08684 2/20 0.40
AR P10275 2/20 0.40
CES2 O00748 1/20 0.40
ABCB11 O95342 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
GLA P06280 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
TBXA2R P21731 1/20 0.40
AADAC P22760 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31122003 1.00 ALDH1A1 (0.49) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2
SCHEMBL28300945 0.83 ALDH1A1 (0.46) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2
SCHEMBL2524312 0.82 TDP1 (0.58) ALDH1A1TDP1TSHRSMN1; SMN2GPR35
SCHEMBL2431059 0.81 TDP1 (0.64) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2
SCHEMBL30800293 0.81 TDP1 (0.64) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2
SCHEMBL16852115 0.78 ALDH1A1 (0.42) ALDH1A1TDP1NPSR1SMN1; SMN2GPR35
SCHEMBL4725240 0.77 TDP1 (0.48) ALDH1A1TDP1TSHRSMN1; SMN2GPR35
SCHEMBL3038035 0.77 RAB9A (0.48) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2
SCHEMBL30627320 0.76 ALDH1A1 (0.50) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2
SCHEMBL1999849 0.76 ALDH1A1 (0.50) ALDH1A1TDP1NPSR1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
WO-2020163236-A1 TREATING LONG QT SYNDROME THE GENERAL HOSPITAL CORPORATION (US) 2020-08-13 WO disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP disclosed
CN-107295799-A Parg inhibiting compounds 癌症研究科技有限公司 2017-10-24 CN disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 ALDH1A1 1411/4885TDP1 233/4885NPSR1 4088/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 ALDH1A1 1411/4885TDP1 233/4885NPSR1 4088/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 ALDH1A1 1483/4885TDP1 223/4885NPSR1 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.